HTA25 Factors Including Real-World Evidence (RWE) That Play a Role in the HTA Recommendation of Oncology Drug Submissions Based on Phase II and/or Single Arm Trial Data

Abstract

Perform a descriptive analysis to understand influential factors including RWE in health technology assessment (HTA) decision-making when assessing oncology submissions with phase II / single arm trial data.